ArticleHaematologica2026

Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.

Ao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.